Kyle J Moody
Examiner (ID: 8172, Phone: (571)272-5242 , Office: P/2838 )
Most Active Art Unit | 2838 |
Art Unit(s) | 2838 |
Total Applications | 778 |
Issued Applications | 667 |
Pending Applications | 60 |
Abandoned Applications | 51 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 18753998
[patent_doc_number] => 20230357358
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-09
[patent_title] => IL-7R-ALPHA-GAMMA BINDING COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 18/350543
[patent_app_country] => US
[patent_app_date] => 2023-07-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 63104
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 250
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18350543
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/350543 | IL-7R-a-g binding compounds | Jul 10, 2023 | Issued |
Array
(
[id] => 19105813
[patent_doc_number] => 11958894
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-16
[patent_title] => Anti-VEGF protein compositions and methods for producing the same
[patent_app_type] => utility
[patent_app_number] => 18/213779
[patent_app_country] => US
[patent_app_date] => 2023-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 60
[patent_figures_cnt] => 86
[patent_no_of_words] => 67491
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18213779
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/213779 | Anti-VEGF protein compositions and methods for producing the same | Jun 22, 2023 | Issued |
Array
(
[id] => 18770835
[patent_doc_number] => 20230365635
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-16
[patent_title] => Activatable Therapeutic Peptides and Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 18/181942
[patent_app_country] => US
[patent_app_date] => 2023-03-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8080
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18181942
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/181942 | Activatable Therapeutic Peptides and Uses Thereof | Mar 9, 2023 | Pending |
Array
(
[id] => 19242025
[patent_doc_number] => 12012444
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-18
[patent_title] => Anti-VEGF protein compositions and methods for producing the same
[patent_app_type] => utility
[patent_app_number] => 18/116166
[patent_app_country] => US
[patent_app_date] => 2023-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 60
[patent_figures_cnt] => 86
[patent_no_of_words] => 67553
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18116166
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/116166 | Anti-VEGF protein compositions and methods for producing the same | Feb 28, 2023 | Issued |
Array
(
[id] => 18724333
[patent_doc_number] => 20230338471
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => LIQUID FORMULATIONS COMPRISING MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES
[patent_app_type] => utility
[patent_app_number] => 18/165081
[patent_app_country] => US
[patent_app_date] => 2023-02-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23838
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 174
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18165081
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/165081 | Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates | Feb 5, 2023 | Issued |
Array
(
[id] => 18753991
[patent_doc_number] => 20230357348
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-09
[patent_title] => GLP-1 AND GLUCAGON DUAL AGONIST PEPTIDES WITH IMPROVED BIOLOGICAL STABILITY
[patent_app_type] => utility
[patent_app_number] => 18/164802
[patent_app_country] => US
[patent_app_date] => 2023-02-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28978
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18164802
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/164802 | GLP-1 AND GLUCAGON DUAL AGONIST PEPTIDES WITH IMPROVED BIOLOGICAL STABILITY | Feb 5, 2023 | Pending |
Array
(
[id] => 18434389
[patent_doc_number] => 20230181683
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => PEPTIDES HAVING SPECIFICITY FOR THE LUNGS
[patent_app_type] => utility
[patent_app_number] => 18/162833
[patent_app_country] => US
[patent_app_date] => 2023-02-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10447
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18162833
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/162833 | PEPTIDES HAVING SPECIFICITY FOR THE LUNGS | Jan 31, 2023 | Pending |
Array
(
[id] => 18552143
[patent_doc_number] => 20230250152
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-10
[patent_title] => CTLA-4 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/161799
[patent_app_country] => US
[patent_app_date] => 2023-01-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 73258
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -38
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18161799
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/161799 | CTLA-4 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF | Jan 29, 2023 | Pending |
Array
(
[id] => 18647992
[patent_doc_number] => 20230293775
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => BONE-PROMOTING THERMORESPONSIVE MACROMOLECULES
[patent_app_type] => utility
[patent_app_number] => 18/158746
[patent_app_country] => US
[patent_app_date] => 2023-01-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5389
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18158746
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/158746 | BONE-PROMOTING THERMORESPONSIVE MACROMOLECULES | Jan 23, 2023 | Pending |
Array
(
[id] => 18361363
[patent_doc_number] => 20230142954
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-11
[patent_title] => ACE INHIBITORY PEPTIDE COMPOSITION DERIVED FROM GINKGO PROTEIN AND PREPARATION METHOD AND APPLICATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/157081
[patent_app_country] => US
[patent_app_date] => 2023-01-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7655
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 392
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18157081
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/157081 | ACE inhibitory peptide composition derived from ginkgo protein and preparation method and application thereof | Jan 19, 2023 | Issued |
Array
(
[id] => 18389825
[patent_doc_number] => 20230158043
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => PHARMACEUTICAL PREPARATION FOR IMPROVING ABSORPTION AND POSTPRANDIAL HYPOGLYCEMIC ACTION OF INSULIN
[patent_app_type] => utility
[patent_app_number] => 18/156633
[patent_app_country] => US
[patent_app_date] => 2023-01-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5854
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18156633
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/156633 | PHARMACEUTICAL PREPARATION FOR IMPROVING ABSORPTION AND POSTPRANDIAL HYPOGLYCEMIC ACTION OF INSULIN | Jan 18, 2023 | Pending |
Array
(
[id] => 18596078
[patent_doc_number] => 20230270869
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => PHOSPHATIDYLSERINE-BINDING CONJUGATES
[patent_app_type] => utility
[patent_app_number] => 18/090259
[patent_app_country] => US
[patent_app_date] => 2022-12-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14749
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18090259
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/090259 | PHOSPHATIDYLSERINE-BINDING CONJUGATES | Dec 27, 2022 | Pending |
Array
(
[id] => 19505011
[patent_doc_number] => 12116422
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-15
[patent_title] => Stapled peptide and use thereof in preparation of drug for treating pancreatic cancer
[patent_app_type] => utility
[patent_app_number] => 18/064719
[patent_app_country] => US
[patent_app_date] => 2022-12-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 24
[patent_no_of_words] => 4321
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 90
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18064719
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/064719 | Stapled peptide and use thereof in preparation of drug for treating pancreatic cancer | Dec 11, 2022 | Issued |
Array
(
[id] => 18449716
[patent_doc_number] => 20230190992
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => HEMOSTATIC MATERIAL COMPOSITION
[patent_app_type] => utility
[patent_app_number] => 18/062577
[patent_app_country] => US
[patent_app_date] => 2022-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9189
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18062577
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/062577 | HEMOSTATIC MATERIAL COMPOSITION | Dec 6, 2022 | Pending |
Array
(
[id] => 18808641
[patent_doc_number] => 20230382975
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-30
[patent_title] => MEANS AND METHODS FOR TREATING AND DIAGNOSING FIBROSIS OR FIBROSIS-ASSOCIATED DISEASES
[patent_app_type] => utility
[patent_app_number] => 18/058131
[patent_app_country] => US
[patent_app_date] => 2022-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26660
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18058131
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/058131 | MEANS AND METHODS FOR TREATING AND DIAGNOSING FIBROSIS OR FIBROSIS-ASSOCIATED DISEASES | Nov 21, 2022 | Pending |
Array
(
[id] => 18603433
[patent_doc_number] => 11744873
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-09-05
[patent_title] => Compositions and methods for the treatment of metabolic and liver disorders
[patent_app_type] => utility
[patent_app_number] => 17/990629
[patent_app_country] => US
[patent_app_date] => 2022-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13915
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 121
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17990629
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/990629 | Compositions and methods for the treatment of metabolic and liver disorders | Nov 17, 2022 | Issued |
Array
(
[id] => 18725835
[patent_doc_number] => 20230340058
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => RELAXIN-2 FUSION PROTEIN ANALOGS AND METHODS OF USING SAME
[patent_app_type] => utility
[patent_app_number] => 18/054596
[patent_app_country] => US
[patent_app_date] => 2022-11-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22957
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 1
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18054596
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/054596 | RELAXIN-2 FUSION PROTEIN ANALOGS AND METHODS OF USING SAME | Nov 10, 2022 | Pending |
Array
(
[id] => 18582869
[patent_doc_number] => 20230265126
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-24
[patent_title] => UBIQUITIN HIGH AFFINITY CYCLIC PEPTIDES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/982883
[patent_app_country] => US
[patent_app_date] => 2022-11-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26613
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17982883
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/982883 | Ubiquitin high affinity cyclic peptides and methods of use thereof | Nov 7, 2022 | Issued |
Array
(
[id] => 18626786
[patent_doc_number] => 20230285594
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-14
[patent_title] => COMPLEXATION OF NUCLEIC ACIDS WITH DISULFIDE-CROSSLINKED CATIONIC COMPONENTS FOR TRANSFECTION AND IMMUNOSTIMULATION
[patent_app_type] => utility
[patent_app_number] => 18/052529
[patent_app_country] => US
[patent_app_date] => 2022-11-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40779
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18052529
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/052529 | COMPLEXATION OF NUCLEIC ACIDS WITH DISULFIDE-CROSSLINKED CATIONIC COMPONENTS FOR TRANSFECTION AND IMMUNOSTIMULATION | Nov 2, 2022 | Pending |
Array
(
[id] => 18451523
[patent_doc_number] => 20230192801
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => NOVEL INSULIN ANALOGUES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/961438
[patent_app_country] => US
[patent_app_date] => 2022-10-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16579
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17961438
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/961438 | NOVEL INSULIN ANALOGUES AND USES THEREOF | Oct 5, 2022 | Pending |